Novelix Pharma.

What is the technical trend for Novelix Pharma.?

As of May 27, 2025, Novelix Pharma's technical trend is mildly bullish, supported by positive momentum from the MACD and RSI, although caution is advised due to a mildly bearish KST.

As of 27 May 2025, the technical trend for Novelix Pharma has changed from bullish to mildly bullish. The weekly MACD and RSI are both bullish, indicating positive momentum in the short term. The daily moving averages also reflect a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly, while the Dow Theory indicates no trend weekly but mildly bullish monthly. Overall, the current stance is mildly bullish, supported by strong monthly indicators and daily moving averages, despite some mixed signals from the KST.

Who are the peers of the Novelix Pharma.?

Novelix Pharma's peers include Khemani Distrib., M K Exim India, MRP Agro, and others, with varying management risks and growth rates. Notably, Novelix Pharma has the highest 1-year return at 138.43%, significantly outperforming its peers.

Peers: The peers of Novelix Pharma are Khemani Distrib., M K Exim India, MRP Agro, Sattva Sukun, Silgo Retail, Purv Flexi, Magson Retail, Osia Hyper Reta., Fonebox Retail, and Cell Point.<BR><BR>Quality Snapshot: Excellent management risk is observed at Khemani Distrib., M K Exim India, MRP Agro, Magson Retail, and Osia Hyper Reta., while Average management risk is found at Cell Point. Below Average management risk is noted for Novelix Pharma., Sattva Sukun, Silgo Retail, Purv Flexi, and Fonebox Retail. Growth is Excellent at M K Exim India and Osia Hyper Reta., Good at MRP Agro and Sattva Sukun, while Below Average growth is seen at Novelix Pharma., Silgo Retail, Purv Flexi, and the rest. Capital Structure is Excellent at Khemani Distrib. and M K Exim India, Good at MRP Agro and Sattva Sukun, while Below Average capital structure is noted for Novelix Pharma., Silgo Retail, Purv Flexi, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Novelix Pharma. at 138.43%, while the lowest is M K Exim India at -4.79%. Novelix Pharma.'s 1-year return significantly outperforms all peers. Additionally, Sattva Sukun, MRP Agro, and Silgo Retail have negative six-month returns.

Who are in the management team of Novelix Pharma.?

As of March 2023, the management team of Novelix Pharma includes Arvind Kumar Bhangadia (Non Executive Director), Natwarlal Ramgopal Modani, Sagar Rajendra Karwa, and Monam Kapoor (all Independent Directors), Aditya Bhangadia (Managing Director), and Ravi Bhangadia (Chairman & Wholetime Director). Each member contributes to the company's strategic direction and governance.

As of March 2023, the management team of Novelix Pharma includes the following individuals:<BR><BR>1. Arvind Kumar Bhangadia - Non Executive Director<BR>2. Natwarlal Ramgopal Modani - Independent Director<BR>3. Sagar Rajendra Karwa - Independent Director<BR>4. Monam Kapoor - Independent Director<BR>5. Aditya Bhangadia - Managing Director<BR>6. Ravi Bhangadia - Chairman & Wholetime Director<BR><BR>Each member plays a significant role in guiding the company's strategic direction and governance.

What does Novelix Pharma. do?

Novelix Pharmaceuticals Ltd is a micro-cap pharmaceutical company that transitioned from finance to drug development after its incorporation in 1994. As of March 2025, it reported net sales of 209 Cr and a net profit of 2 Cr.

Overview: <BR>Novelix Pharmaceuticals Ltd operates in the pharmaceutical and drug industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 1994 under the name Trimurthi Securities Ltd. It initially engaged in finance and investments in securities but ceased operations due to market volatility and voluntarily de-registered as a Non-Banking financial company. Subsequently, it diversified into the pharmaceutical sector. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 209 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 116 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.24 <BR>Return on Equity: -30.14% <BR>Price to Book: 16.72<BR><BR>Contact Details: <BR>Address: 4-4-231/1/2/ABC Inderbagh, Sultan Bazar Hyderabad Telangana : 500095 <BR>Tel: 91-40-24757370 <BR>Email: info@trimurthidrugs.com <BR>Website: http://www.trimurthidrugs.com

Who are the top shareholders of the Novelix Pharma.?

The top shareholders of Novelix Pharma are Srinidhi Fine-chemicals LLP with 38.67%, followed by Mallela Venkatramna Reddy at 11.6%, and individual investors holding 36.84%. There are currently no mutual funds or foreign institutional investors involved.

The top shareholders of Novelix Pharma include Srinidhi Fine-chemicals LLP, which holds the largest stake at 38.67%. The highest public shareholder is Mallela Venkatramna Reddy, who owns 11.6%. Additionally, individual investors collectively hold 36.84% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

How big is Novelix Pharma.?

As of 24th July, Novelix Pharmaceuticals Ltd has a market capitalization of 111.00 Cr and reported Net Sales of 4.40 Cr with a Net Profit loss of 2.17 Cr over the latest four quarters. Shareholder's Funds were 7.40 Cr and Total Assets were 8.67 Cr as of March 2022.

As of 24th July, Novelix Pharmaceuticals Ltd has a market capitalization of 111.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Novelix Pharmaceuticals reported Net Sales of 4.40 Cr. However, the company experienced a Net Profit loss of 2.17 Cr during the same period.<BR><BR>For the latest annual period ending in March 2022, the Shareholder's Funds were recorded at 7.40 Cr, while Total Assets amounted to 8.67 Cr.

Is Novelix Pharma. overvalued or undervalued?

As of November 27, 2025, Novelix Pharma is considered very expensive and overvalued with a PE ratio of 97.12, significantly higher than its peers, despite a strong stock performance of 148.52% over the past year.

As of 27 November 2025, the valuation grade for Novelix Pharma has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 97.12, an EV to EBIT of 70.40, and an EV to EBITDA of 68.28. These ratios are starkly higher than its peers, such as Sun Pharma with a PE of 37.62 and Divi's Lab at 69.34, both categorized as very expensive.<BR><BR>In comparison to its industry peers, Novelix Pharma's valuation metrics suggest it is not only overvalued but also out of sync with more attractively priced competitors like Cipla and Dr Reddy's Labs, which have PE ratios of 22.67 and 18.08, respectively. While Novelix has shown impressive stock performance over the past year with a return of 148.52% compared to the Sensex's 6.84%, this does not justify its current high valuation levels.

How has been the historical performance of Novelix Pharma.?

Novelix Pharma has experienced a declining trend in net sales and profitability, with significant losses reported since March 2020, including a net loss of -2.12 Cr in March 2022. Despite these challenges, the company's cash position improved, indicating some liquidity stability.

Answer:<BR>The historical performance of Novelix Pharma shows a declining trend in net sales and profitability over the past several years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Novelix Pharma's net sales have decreased from 10.50 Cr in March 2018 to 8.61 Cr in March 2022, reflecting a downward trend. The total operating income also followed this decline, dropping from 10.50 Cr in March 2018 to 8.61 Cr in March 2022. The company's total expenditure, excluding depreciation, peaked at 13.04 Cr in March 2021 but fell to 11.18 Cr in March 2022. Operating profit (PBDIT) has consistently been negative since March 2020, with a loss of -2.02 Cr reported in March 2022. Profit before tax and profit after tax also remained negative, with losses of -2.12 Cr and -2.12 Cr, respectively, in March 2022. The company's earnings per share (EPS) worsened from -0.01 in March 2017 to -2.22 in March 2022. Despite these challenges, the company's cash and cash equivalents improved from 0.59 Cr in March 2017 to 2.00 Cr in March 2022, indicating some liquidity stability. Overall, Novelix Pharma's financial performance has shown significant challenges, particularly in revenue generation and profitability, while maintaining a stable cash position.

When is the next results date for Novelix Pharmaceuticals Ltd?

The next results date for Novelix Pharmaceuticals Ltd is 12 February 2026.

The next results date for Novelix Pharmaceuticals Ltd is scheduled for 12 February 2026.

Are Novelix Pharmaceuticals Ltd latest results good or bad?

Novelix Pharmaceuticals Ltd's latest results show a return to profitability with a net profit of ₹1.00 crore and record net sales of ₹48.40 crores; however, concerns about low Return on Equity, high P/E ratio, and a low Mojo Score suggest caution regarding its long-term prospects.

Novelix Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company has returned to profitability with a net profit of ₹1.00 crore in Q3 FY26, marking a significant turnaround from previous losses. Additionally, net sales reached ₹48.40 crores, the highest quarterly revenue in the company's history, which is a positive indicator of operational improvement.<BR><BR>However, despite these encouraging results, there are underlying concerns. The company's average Return on Equity (ROE) over the past five years is a mere 0.74%, indicating weak capital efficiency and a struggle to generate meaningful returns for shareholders. Furthermore, the stock's high P/E ratio of 114x suggests that it is currently overvalued relative to its earnings potential, raising questions about sustainability.<BR><BR>The company's Mojo Score is also low at 48 out of 100, leading to a "SELL" recommendation, reflecting ongoing concerns about its long-term fundamental strength. Additionally, the decline in promoter holding and the absence of institutional investors signal a lack of confidence in the company's future prospects.<BR><BR>In summary, while Novelix Pharmaceuticals has shown signs of recovery with its latest results, significant risks and valuation concerns remain, making the overall assessment cautious.

Should I buy, sell or hold Novelix Pharmaceuticals Ltd?

Why is Novelix Pharmaceuticals Ltd falling/rising?

As of 03-Apr, Novelix Pharmaceuticals Ltd's stock price is Rs 51.65, down 4.28%, reflecting a consistent downward trend with a 10.62% loss over the past week. Despite increased investor participation, the stock remains below several moving averages, indicating bearish sentiment.

As of 03-Apr, Novelix Pharmaceuticals Ltd's stock price is falling, currently at Rs 51.65, which reflects a decrease of Rs 2.31 or 4.28%. The stock has been underperforming, having lost 10.62% over the past week and 9.73% over the past month, indicating a consistent downward trend. Today, the stock has underperformed its sector by 3.45% and has experienced a consecutive decline over the last two days, with a total drop of 7.4% during this period. <BR><BR>Additionally, the stock reached an intraday low of Rs 50.01, which is a significant decline of 7.32%. Despite the stock being higher than its 200-day moving average, it is currently lower than its 5-day, 20-day, 50-day, and 100-day moving averages, suggesting a bearish trend in the short to medium term. <BR><BR>On a positive note, there has been a notable increase in investor participation, with delivery volume rising by 955.71% against the 5-day average, indicating some interest in trading the stock. However, the overall liquidity remains adequate for trading, but the negative performance metrics suggest that the stock is currently facing downward pressure.

Why is Novelix Pharmaceuticals Ltd falling/rising?

As of 04-Apr, Novelix Pharmaceuticals Ltd's stock price is declining at 51.65, down 4.28%. This decline is driven by significant recent underperformance and negative investor sentiment, despite some positive long-term growth indicators.

As of 04-Apr, Novelix Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 51.65, which reflects a change of -2.31 (-4.28%). This downward movement can be attributed to several factors. Over the past week, the stock has underperformed significantly, with a decrease of -10.62%, compared to a smaller decline of -2.60% in the Sensex. Additionally, the stock has fallen -7.4% over the last two days, indicating a consecutive decline.<BR><BR>Today's trading session saw the stock reach an intraday low of Rs 50.01, marking a drop of -7.32%. The weighted average price suggests that more volume was traded closer to this low price, indicating selling pressure. Furthermore, while the stock is trading higher than its 200-day moving averages, it remains below the 5-day, 20-day, 50-day, and 100-day moving averages, which may signal a bearish trend.<BR><BR>Despite some positive long-term growth indicators, such as a healthy annual growth rate in net sales of 153.19% and a net profit growth of 88.68%, the recent performance metrics and the stock's current trajectory suggest that investor sentiment is currently negative, leading to the observed price decline.

Why is Novelix Pharmaceuticals Ltd falling/rising?

As of 05-Apr, Novelix Pharmaceuticals Ltd's stock price is Rs 51.65, down 4.28%, with a total decline of 7.4% over the last two days. Despite strong long-term growth indicators, short-term performance reflects a lack of investor confidence, leading to a negative outlook.

As of 05-Apr, Novelix Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 51.65, which reflects a change of -2.31 (-4.28%). The stock has underperformed its sector by 3.45% today and has been on a consecutive fall for the last two days, resulting in a total decline of 7.4% during this period. The stock also touched an intraday low of Rs 50.01, indicating significant selling pressure.<BR><BR>In terms of performance over the past week, the stock has decreased by 10.62%, while the benchmark Sensex has only fallen by 2.60%. Over the past month, the stock is down 9.73%, compared to an 8.62% decline in the Sensex. Year-to-date, Novelix Pharmaceuticals has seen a drop of 17.52%, which is more substantial than the Sensex's 13.96% decrease.<BR><BR>Despite some positive long-term growth indicators, such as a healthy annual growth rate in net sales of 153.19% and a net profit growth of 88.68%, the recent performance metrics suggest a lack of investor confidence in the short term. The stock's moving averages indicate that it is currently lower than the 5-day, 20-day, 50-day, and 100-day moving averages, although it remains above the 200-day moving average. This mixed performance, combined with rising investor participation and liquidity, suggests that while there may be potential for recovery, the immediate outlook is negative, contributing to the current decline in stock price.

Which are the latest news on Novelix Pharma.?